

PTO/SB/08b (08-08)

Approved for use through 09/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/772,090
				Filing Date	February 3, 2004
				First Named Inventor	Margaret H. Baron
				Art Unit	1646
				Examiner Name	Z. C. Howard
Sheet	1	of	2	Attorney Docket Number	HUIP-P02-060

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AI2	7,445,778	11-04-2008	Burkly et al.	
	AJ2	7,498,304	03-03-2009	Kotkow et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BQ	WO-00/25725	05-11-2000	Biogen, Inc.		
	BR	WO-00/74706	12-14-2000	Lorantis Limited		
	BS	WO-01/19800	03-22-2001	Curis, Inc.		
	BT	WO-01/26644	04-19-2001	Curis, Inc.		
	BU	WO-01/74344	10-11-2001	Curis, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CG4	Bian et al. 2007. "Sonic hedgehog-Gli1 pathway in colorectal adenocarcinomas". <i>World J. Gastroenterol.</i> 13(11): pp. 1659-1665.	
	CH4	Douard et al. 2006. "Sonic Hedgehog-dependent proliferation in a series of patients with colorectal cancer". <i>Surgery.</i> 139: pp. 665-670.	
	CI4	Ellis et al. 2000. "Vascular Endothelial Growth Factor in Human Colon Cancer: Biology and Therapeutic Implications". <i>The Oncologist.</i> 5(Suppl 1): pp. 11-15.	
	CJ4	Fang et al. 2007. "Apigenin inhibits tumor angiogenesis through decreasing HIF-1 $\alpha$ and VEGF expression". <i>Carcinogenesis.</i> 28(4): pp. 858-864.	
	CK4	Hu et al. 1993. "[Leu <sup>8</sup> ]des-Arg <sup>9</sup> -bradykinin inhibits the angiogenic effect of bradykinin and interleukin-1 in rats". <i>Br.J.Pharmacol.</i> 109: pp. 14-17.	
	CL4	Palis et al. 1995. "Initiation of Hematopoiesis and Vasculogenesis in Murine Yolk Sac Explants". <i>Blood.</i> 86(1): pp. 156-163.	
	CM4	Robertson et al. 1991. "A Quantitative in Vivo Mouse Model Used to Assay Inhibitors of Tumor-induced Angiogenesis". <i>Cancer Research.</i> 51: pp. 1339-1344.	
	CN4	Rochette et al. 2005. "SW480, a p53 Double-mutant Cell Line Retains Proficiency for Some p53 Functions". <i>J. Mol. Biol.</i> 352(1): pp. 44-57.	
	CO4	Schulz et al. 2006. "Understanding urothelial carcinoma through cancer pathways". <i>Int. J.</i>	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/772,090
				Filing Date	February 3, 2004
				First Named Inventor	Margaret H. Baron
				Art Unit	1646
				Examiner Name	Z. C. Howard
Sheet	2	of	2	Attorney Docket Number	HUIP-P02-060

		<i>Cancer</i> . 119: pp. 1513-1518.	
	CP4	Sheng et al. 2004. "Activation of the hedgehog pathway in advanced prostate cancer". <i>Molecular Cancer</i> . 3(29) pp. 1-13.	
	CQ4	Thayer et al. 2003. "Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis". <i>Nature</i> . 425: pp. 851-856.	
	CR4	Teunis et al. 2002. "Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperactive dopa-minergic system". <i>Faseb Journal</i> . 16: pp. 1465-1467.	
	CS4	Yauch et al. 2008. "A paracrine requirement for hedgehog signalling in cancer". <i>Nature</i> . 455: pp. 406-410.	
	CT4	Yoshida et al. 2003. "COX-2/VEGF-Dependent Facilitation of Tumor-Associated Angiogenesis and Tumor Growth In Vivo". <i>Laboratory Investigation</i> . 83(10): pp. 1385-1394.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: <u>4/9/09</u>	Signature: <u></u> (Ginny Blundell)